sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?
Ključne riječi
Sažetak
Opis
Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures. (Limit : 32 000 characters)
The soluble fms-like tyrosine kinase 1 (SFlt1) is the soluble form of VEGF-A receptor 1 (VEGFR1). By linking VEGF-A with a high affinity, sFlt1 blocks the VEGF-A / VEFR1 axis and impairs endothelial homeostasis. Its production increases during inflammation. We hypothesize that sFlt1 is upregulated and correlates with endothelial dysfunction and outcomes in critically-ill patients with COVID-19.
Datumi
| Posljednja provjera: | 04/30/2020 |
| Prvo podneseno: | 05/15/2020 |
| Predviđena prijava poslana: | 05/15/2020 |
| Prvo objavljeno: | 05/18/2020 |
| Posljednje ažuriranje poslano: | 05/15/2020 |
| Posljednje ažuriranje objavljeno: | 05/18/2020 |
| Stvarni datum početka studija: | 03/24/2020 |
| Procijenjeni datum primarnog završetka: | 06/30/2020 |
| Procijenjeni datum završetka studije: | 08/31/2020 |
Stanje ili bolest
Intervencija / liječenje
Other: patients with COVID-19 infection
Faza
Grupe ruku
| Ruka | Intervencija / liječenje |
|---|---|
| patients with COVID-19 infection patients with COVID-19 infection | Other: patients with COVID-19 infection blood circulating sFlt1 concentration will be determined |
Kriterij prihvatljivosti
| Dobni uvjeti za studiranje | 18 Years Do 18 Years |
| Spolovi koji ispunjavaju uvjete za studij | All |
| Metoda uzorkovanja | Non-Probability Sample |
| Prihvaća zdrave volontere | Da |
| Kriteriji | Inclusion Criteria: - Patient with documented COVID-19 (positive PCR) - Hospitalized in University Hospital of Reims - Patient or family who have previously consented Exclusion Criteria: - Patient <18 yo - Patient not insured under the French social security |
Ishod
Primarne mjere ishoda
1. Association between concentration of circulating sFlt1 and use of vasopressor [14 days]
